share_log

港股异动 | 锦欣生殖(01951)涨超7% 多地辅助生殖项目进医保 机构看好公司市占率提升

HK Stock Market News | jxr (01951) surged more than 7%, assisted reproduction projects in multiple regions included in medical insurance, institutions bullish on company's market share increase.

Zhitong Finance ·  Sep 24 01:57

JXR (01951) rose more than 7%, as of the time of publication, it increased by 7.49%, closing at HKD 2.44, with a turnover of 36.1502 million Hong Kong dollars.

According to the Futu Securities app, JXR (01951) rose more than 7%, as of the time of publication, it increased by 7.49%, closing at HKD 2.44, with a turnover of 36.1502 million Hong Kong dollars.

On the news front, in recent times, many places have announced the inclusion of multiple assisted reproduction medical projects in medical insurance. Hubei Province will include 8 assisted reproduction medical service projects such as "egg retrieval" in the scope of medical insurance payments, effective from September 15; Guangdong Province will include 8 assisted reproduction medical service projects such as "egg retrieval" in the scope of medical insurance payments, effective from October 1; Yunnan Province will include 12 assisted reproduction medical service projects such as "egg retrieval" in the scope of medical insurance payments, effective from October 10.

It is reported that starting from 2023, Beijing and Guangxi will include assisted reproduction in the scope of medical insurance reimbursement, followed by many provinces. By September 2024, it has reached 20 provinces. In addition, Guangdong and Yunnan will also be explicitly included in October, by then, at least 22 provinces will include assisted reproduction in medical insurance. Haitong Int'l believes that the policy of including assisted reproduction in medical insurance is gradually advancing, which is expected to catalyze the company's performance. Huachuang Securities stated that considering the future acceleration of the penetration rate of assisted reproduction into medical insurance, with its strong operational integration capabilities, excellent brand, and platform, the company's market share (number of egg retrieval cycles) is expected to steadily increase.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment